The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; 43 of the 75 sources its claims cite were checked for support.
Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56
Open accessAbstract
Protein phosphatase 2A (PP2A) is a critical human tumor suppressor. Cancerous inhibitor of PP2A (CIP2A) supports the activity of several critical cancer drivers (Akt, MYC, E2F1) and promotes malignancy in most cancer types via PP2A inhibition. However, the 3D structure of CIP2A has not been solved, and it remains enigmatic how it interacts with PP2A. Here, we show by yeast two-hybrid assays, and subsequent validation experiments, that CIP2A forms homodimers. The homodimerization of CIP2A is confirmed by solving the crystal structure of an N-terminal CIP2A fragment (amino acids 1-560) at 3.0 Å resolution, and by subsequent structure-based mutational analyses of the dimerization interface. We further describe that the CIP2A dimer interacts with the PP2A subunits B56α and B56γ. CIP2A binds to the B56 proteins via a conserved N-terminal region, and dimerization promotes B56 binding. Intriguingly, inhibition of either CIP2A dimerization or B56α/γ expression destabilizes CIP2A, indicating opportunities for controlled degradation. These results provide the first structure-function analysis of the interaction of CIP2A with PP2A/B56 and have direct implications for its targeting in cancer therapy.
Overview
CoChat Summary
## TL;DR
This study reports the first crystal structure of CIP2A and shows that CIP2A forms homodimers via a C-terminal three-helix dimerization interface. It also shows that CIP2A directly binds the PP2A B56a and B56c subunits, and that this binding is promoted by dimerization and contributes to CIP2A protein stability.
## Key findings
- Yeast two-hybrid screening with full-length CIP2A as bait identified CIP2A itself as a high-confidence interaction partner; selected interaction domain analysis mapped the homodimerization region to amino acids 388–558, with the crystallized fragment CIP2A(1–560) behaving as a dimer.
- The CIP2A(1–560) crystal structure was solved at 3.0 Å resolution; SEC-MALS gave a molecular mass of 117.2 kDa for CIP2A(1–560), consistent with a dimer (calculated 124.5 kDa).
- Mutations in the dimer interface reduced dimerization: L533E inhibited dimerization by up to 70%, and R522D caused about 50% inhibition; both mutations also reduced B56a binding.
- CIP2A directly interacted with PP2A B56 subunits B56a and B56c, with the minimal N-terminal B56-binding region mapped to amino acids 159–245; one mutant, N230E, significantly inhibited B56a binding.
- Disrupting CIP2A dimerization or depleting B56a/B56c lowered full-length CIP2A protein levels by up to 50% in HEK293T cells, without changing CIP2A mRNA; the L533E effect was also validated in 22RV1 cells and was associated with reduced pAkt Ser473.
## Methods
- Structural and biochemical study of CIP2A: yeast two-hybrid screening, GST pull-downs, SEC and SEC-MALS, microscale thermophoresis, proximity ligation assay, crystallography, and structure-guided mutagenesis.
- Sample/cell systems: recombinant human CIP2A(1–560) expressed in E. coli for structural and binding assays; HEK293T, HeLa, and 22RV1 cells for interaction and protein-stability experiments; endogenous CIP2A dimerization assessed in HeLa extracts.
- Main analyses: crystal structure determination by SeMet SAD at 3.0 Å; quantitative comparison of wild-type vs mutant dimerization and B56 binding; Western blot and RT-qPCR to test effects on protein and mRNA abundance.
## Limitations
- The authors state that co-crystallization of the CIP2A–B56a complex was “extremely challenging” and remained an ongoing effort, so the exact molecular basis of the interaction was not resolved.
- They note that although N-terminal and dimerization regions were sufficient for B56 binding, the C-terminal sequences and post-translational modifications of full-length CIP2A might also contribute; this is a limitation of the fragment-based structural work.
- Evident from the text: the N-terminal half of CIP2A(1–560) had high B factors and was not fully traceable in the structure, so parts of the model are incomplete.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
27 Valid · 2 Not valid · 6 Not checked · 55 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“the patients with both of these alterations constituted the patient population with clearly the worst outcome [13]”
What the sources say
- Supportedcites [13] Kauko O, Laajala TD, Jumppanen M, Hintsanen P, Suni V, Haapaniemi P, Corthals G, Aittokallio T, Westermarck J, Imanishi SY (2015) Label‐free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling. Sci Rep 5: 13099 source
The Results section reports that high CIP2A expression combined with high KRAS expression was associated with the worst survival in TCGA pan-cancer data. It adds that activating KRAS mutations showed a similar synergistic relationship with CIP2A expression, supporting the claim for patients with both alterations. The mutation analysis was based on a limited number of patients. (LLM, conf=0.86)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“high CIP2A protein expression predicts poor patient survival in over a dozen different cancer types [20]”
What the sources say
- Partly supportedcites [20] Khanna A, Pimanda JE (2015) Clinical significance of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancers. Int J Cancer 138: 525–532 sourceExperimental — accuracy not yet measured
The Prognostic Role section says CIP2A expression has an established prognostic role in over 10 tumor types and reports associations with poorer survival in several cancers. It does not establish the claim’s more specific count of over a dozen types with poor survival predicted by high CIP2A protein expression; the section also notes conflicting prognostic findings. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“PP2A complex components are mutated at a relatively low frequency in most types of human cancer”
What the sources say
- Partly supportedcites [2] Perrotti D, Neviani P (2013) Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol 14: e229–e238 sourceExperimental — accuracy not yet measured
Section 3, “PP2A in disease and cancer” (page unavailable), reports PR65β mutations in 13–15% of several primary cancers and PR65α alterations in 6.7–19.2% of several tumor categories. These figures support relatively low frequencies in the examples given, but the passage does not establish that PP2A complex components generally are mutated at low frequency in most types of human cancer; it also reports PR65α alterations in 43% of primary gliomas. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [6] Khanna A, Pimanda JE, Westermarck J (2013) Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. Cancer Res 73: 6548–6553 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“CIP2A overexpression is required for RAS-driven human cell transformation [10]”
What the sources say
- Partly supportedcites [10] Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, Ala‐aho R, Nielsen C, Ivaska J, Taya Y et al (2007) CIP2A inhibits PP2A in human malignancies. Cell 130: 51–62 sourceExperimental — accuracy not yet measured
The Discussion reports that CIP2A expression transforms human HEK-TERV cells immortalized by Ras, TERT, and large-T antigen. This supports a role for CIP2A in that transformation model, but it does not establish that CIP2A overexpression is required for RAS-driven human cell transformation generally. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“we recently demonstrated significant overlap between CIP2A and RAS-regulated phosphoproteomes [13]”
What the sources say
- Supportedcites [13] Kauko O, Laajala TD, Jumppanen M, Hintsanen P, Suni V, Haapaniemi P, Corthals G, Aittokallio T, Westermarck J, Imanishi SY (2015) Label‐free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling. Sci Rep 5: 13099 source
The Discussion (page not provided) says the integrated results revealed extensive overlap between the CIP2A- and RAS-regulated phosphoproteomes. The Abstract also reports significant overlap in their functional pathways. (LLM, conf=0.92)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
51 more claims · 9 with their cited sources checked
Create a free account to see all 90 claims and every source verdict.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 12
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alternatively, selective B subunit inhibition has also been characterized through the overexpression of endogenous PP2A inhibitors such as the Cancerous Inhibitor of PP2A (CIP2A) which selectively sequesters B56 family subunits to prevent B56 specific PP2A holoenzyme activity (Junttila et al., 2007; Wang et al., 2017).”
From Selective PP2A enhancement through biased heterotrimer stabilization (2020) · cites this paper as Wang et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, similar to CIP2A, NOCIVA retains the capability to dimerize and bind to B56a, indicating that it functions similarly to CIP2A as a PP2A inhibitor protein (1).”
From Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (2021) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The only thus far available structure of CIP2A spans the first 560 amino acids of the protein and reveals that CIP2A is an obligate homodimer interacting with B56 proteins31.”
From Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A (2023) · cites this paper as [31]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Cancerous inhibitor of protein phosphatase 2A (CIP2A) functions as an oncoprotein by directly binding to the tumor suppressor PP2A-B56a (1,2).”
From Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (2021) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“According to this model, CIP2A traps B56 proteins (B56 a and B56 g and possibly other B56 subunits as well).”
From Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis (2019) · cites this paper as Wang et al., 2017
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ CIP 2 A homodimerization
“The SID analysis for interaction between two CIP2A molecules indicated that CIP2A homodimerization is mediated by a region encompassing amino acids 388 -558 (Figs 1A and EV1C).”
§ Figure 1 . Verification of homodimerization of the CIP 2 A( 1 -560 ).
“These results reveal that CIP2A homodimerizes, and suggest that the dimerization is mediated by a region containing amino acids 338 -558.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mutational analysis of CIP 2 A( 1 -560 ) dimerization interface
“Notably, the mode of interference in dimerization by these mutants was reflected with their potency on reducing pulled-down parental CIP2A(1 -560)-V5 protein; L533E inhibited dimerization by up to 70%, whereas R552D being not directly involved in interaction surface caused ~ 50% inhibition (Fig 3D and E).”
§ Generation of CIP 2 A N 230 E, R 522 D, and L 533 E mutants
“R522D and L533E mutations were introduced by PCR, using QuickChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies, TX, USA).”
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,965
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Protein production by auto-induction in high-density shaking cultures
Studier, F. W. (2005) · Protein Expression and Purification · doi:10.1016/j.pep.2005.01.016 · Cited by 5,931
Rules for Making Human Tumor Cells
Hahn, W. C., & Weinberg, R. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra021902 · Cited by 951
Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1110 · Cited by 791
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677
Self-citationProtein phosphatase 2A regulatory subunits and cancer
Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513
Structure of the Protein Phosphatase 2A Holoenzyme
Xu, Y., Xing, Y., Chen, Y., Chao, Y., Lin, Z., Fan, E., Yu, J. W., Strack, S., Jeffrey, P. D., & Shi, Y. (2006) · Cell · doi:10.1016/j.cell.2006.11.033 · Cited by 450 · cited 1×
“We also assumed that the binding on CIP2A may occur at positively charged areas, since B56 surface is largely negatively charged [34,35].”
Cited by
Elgendy, M., Cirò, M., Hosseini, A., Weiszmann, J., Mazzarella, L., Ferrari, E., Cazzoli, R., Curigliano, G., DeCensi, A., Bonanni, B., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.007 · Cited by 299
“A recent study resolved the 3D structure of CIP2A (Wang et al., 2017) and showed that CIP2A forms homodimers, which interact with the PP2A B56 subunits leading to CIP2A stabilization.”
BackgroundMicropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression
Guo, B., Wu, S., Zhu, X., Zhang, L., Deng, J., Li, F., Wang, Y., Zhang, S., Wu, R., Lu, J., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019102190 · Cited by 243
“…report has shown that PP2A’s subunits B56 c and B56 a also bind to the N-terminus of CIP2A (amino acid 159 – 245) to maintain the stability of CIP2A dimer (Wang et al , 2017; Wu et al , 2017), we hypothesized that CIP2A-BP and these two subunits might compete for the same CIP2A binding site.”
Selective PP2A enhancement through biased heterotrimer stabilization
Leonard, D., Huang, W., Izadmehr, S., O’Connor, C. M., Wiredja, D. D., Wang, Z., Zaware, N., Chen, Y., Schlatzer, D. M., Kiselar, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.038 · Cited by 176
“…selective B subunit inhibition has also been characterized through the overexpression of endogenous PP2A inhibitors such as the cancerous inhibitor of PP2A (CIP2A) that selectively sequestersB56 family subunits topreventB56-specificPP2Aholoenzyme activity (Junttila et al., 2007; Wang et al., 2017).”
BackgroundSelf-citationMission Possible: Advances in MYC Therapeutic Targeting in Cancer
Allen-Petersen, B. L., & Sears, R. C. (2019) · BioDrugs · doi:10.1007/s40259-019-00370-5 · Cited by 151
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1093 · Cited by 149
Self-citation
Metadata
- Authors
- Wang, J., Okkeri, J., Pavic, K., Wang, Z., Kauko, O., Halonen, T., Sarek, G., Ojala, P. M., Rao, Z., Xu, W., & Westermarck, J.
- Affiliations
- University of Washington (US)
- Åbo Akademi University (FI)
- University of Helsinki (FI)
- Nankai University (CN)
- Corresponding author
- Xu, Wenqing
- Westermarck, Jukka
- ORCID
- Venue
- The EMBO Reports
- Published
- 2017-02-07
- Volume
- 18
- Issue
- 3
- Pages
- 437-450
- ISSN
- 1469-221X (ISSN-L)
- 1469-3178
- PMC
- PMC5331240
- OpenAlex
- W2586089906
- Cited by
- 95
- References
- 47
- Citations by year
- 2026: 1 · 2025: 10 · 2024: 8 · 2023: 10 · 2022: 12 · 2021: 15 · 2020: 12 · 2019: 13 · 2018: 8 · 2017: 6
- FWCI
- 8.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- EMBO Reports (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Academy of Finland (138963)
- Cancer Society of Finland
- Sigrid Juselius Foundation
- Emil Aaltonen Foundation
- National Cancer Institute (R21CA201944)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CIP2A, protein phosphatase 2A, PP2A-B56, protein dimerization, protein-protein interaction, protein stability, protein degradation, tumor suppressor, crystal structure, structure-function analysis, cancer therapy targets
- MeSH terms
- Autoantigens, Binding Sites, Humans, Membrane Proteins, Models, Molecular, Mutation, Protein Binding, Protein Conformation, Structure-Activity Relationship, Oncogene Proteins, Protein Subunits, Tumor Suppressor Proteins, Protein Interaction Mapping, Intracellular Signaling Peptides and Proteins, Protein Phosphatase 2, Protein Multimerization, Protein Stability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56. https://app.cochat.ai/papers/10.15252/embr.201642788
- The paper
- Wang, J., Okkeri, J., Pavic, K., Wang, Z., Kauko, O., Halonen, T., Sarek, G., Ojala, P. M., Rao, Z., Xu, W., & Westermarck, J. (2017). Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56. The EMBO Reports. https://doi.org/10.15252/embr.201642788
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.